Rheumatoid arthritis (RA) is the most common autoimmune inflammatory arthritis in adults. In June 2021, the ACR released an updated guideline for the treatment of rheumatoid arthritis. The guideline underscores the role of methotrexate as a cornerstone therapy and emphasizes minimizing glucocorticoids, when possible. Meanwhile, the most recent research in RA is explored by expert Jeffrey Curtis, MD, MS, MPH.
FEATURED ARTICLE: The Rheumatic Dangers of Wildfire Smoke
At this ACR Convergence 2025 session, experts discussed the importance of vaccinating immunocompromised patients with non-live vaccines.
Experts discuss high-intensity interval training as an underused “disease-modifying drug” for inflammatory diseases. Learn how to safely integrate it into patient treatment plans.
Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.
New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.
New studies reveal predictors for avoidable RA hospitalizations, PsA transition in psoriasis & the impact of neighborhood on childhood lupus.
Using data from registries across Europe and Canada, Aymon et al. compared the incidence of major adverse cardiac events (MACE) in patients with RA treated with JAK inhibitors, TNF inhibitors or biologic DMARDs with other modes of action over two years. The researchers did not find an increased risk of MACE with JAK inhibitors over that time frame.
Dr. Diane van der Woude reviewed provided a detailed review of the latest research on rheumatoid arthritis, addressing findings on disease prevention, supplements, novel treatments and much more.
A recent study in A&R identifies an association between air pollutants, including fire smoke particulate matter, & both rheumatoid arthritis (RA) & RA-associated interstitial lung disease.
Early study results demonstrate that rosnilimab may be safe and effective for patients with rheumatoid arthritis, reducing the signs and symptoms of RA by week 12 and achieving important primary and secondary study end points.
Risk of Mortality from SLE By Ansaam Daoud, MD, Loai Dweik, MD, & Omer Pamuk, MD Why was this study done? Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with significant mortality, particularly affecting racial and ethnic minorities. This study aimed to assess national SLE mortality trends over the past two decades, stratified by…
Patients with RA not only suffer from functional limitations, but also face increased healthcare costs, primarily due to prescription drug use, says Dr. Yinan Huang.
In this study, researchers set out to determine the prevalence of baseline risk factors for cardiovascular outcomes and cancer among commercially insured patients with rheumatoid arthritis during their first dispensed treatment.
This study affirms that dysbiosis is a feature of rheumatoid arthritis (RA) and suggests that specific therapies may differentially modulate the gastrointestinal microbiota in RA.